July 14, 2009 - Circulating tumor cell (CTC) count could better predict the prognosis and survival in metastatic breast cancer (MBC) patients compared to FDG-PET/CT, according to a newly published report in the July 10 issue of the Journal of Clinical Oncology.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now